Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
salmeterol + fluticasone propionate (invoX Pharma)
- Development stage
- Unknown
- Lead developer
- invoX Pharma
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
SFT-1005 (also known as IXT-004) is a generic combination inhalation therapy consisting of **salmeterol** (a long-acting beta2-adrenergic agonist) and **fluticasone propionate** (a corticosteroid), developed by **invoX Pharma** (a subsidiary of Sino Biopharmaceutical) using the proprietary **Softhaler®** technology. Salmeterol acts as a bronchodilator by stimulating beta2-adrenergic receptors, while fluticasone propionate reduces airway inflammation through glucocorticoid receptor activation. The Softhaler® platform is a propellant-free **soft mist inhaler (SMI)** designed to deliver medication with high lung deposition and low oropharyngeal deposition, independent of the patient's inspiratory flow. SFT-1005 is being developed as a generic alternative to **Advair** (Seretide) for the treatment of **asthma**.
- Brand names
- FixkohFixkoh Airmaster
- Other names
- salmeterol/fluticasone propionatesalmeterol/fluticasone
02
Targets
ADRB1 (β1)MR (Mineralocorticoid receptor)GR (Glucocorticoid receptor)ADRB2 (β2)
Beyond the preview
Go deeper on salmeterol + fluticasone propionate (invoX Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on salmeterol + fluticasone propionate (invoX Pharma).